Market Overview

Myriad Genetics Shares Jump To 9-Month High On Insurance Coverage For Genetic Test

Myriad Genetics Shares Jump To 9-Month High On Insurance Coverage For Genetic Test

Shares of molecular diagnostics company Myriad Genetics, Inc. (NASDAQ: MYGN) were rallying to a nine-month high Thursday on above-average volume.

Myriad shares are reacting to a decision by UnitedHealth Group Inc (NYSE: UNH) to cover pharmacogenetic testing with multigene panels, including the former's GeneSight Psychotropic test.

The test can be used by people diagnosed with depression who have failed at least one medication. It analyzes how the DNA affects the response to depression medications, and assists physicians in prescribing optimal medication.

Myriad shares were rallying by 50.79% to $43.94, their highest level since Nov. 2, 2018.

Related Links:

Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Posted-In: GeneSightBiotech News Trading Ideas General Best of Benzinga


Related Articles (MYGN + UNH)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Stocks Crash After Trump Threatens New Tariffs On $300B In Chinese Goods

This Clean Energy ETF Is Cleaning Up